Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in the 2022 Wedbush Pacgrow Healthcare Conference. The virtual event will feature a fireside chat with the company's senior management team on August 9, 2022, at 4:05 p.m. ET. Investors can access the live webcast on Karyopharm's website under the 'Events & Presentations' section, which will be available for replay for 90 days post-event. Karyopharm is known for pioneering novel cancer therapies and its lead compound, XPOVIO (selinexor), is approved in multiple oncology indications.

NEWTON, Mass., Aug. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 Wedbush Pacgrow Healthcare Conference. The conference is being conducted in a virtual format and the fireside chat will take place on Tuesday, August 9, 2022 at 4:05 p.m. ET.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event. 

About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®), China and Singapore. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-2022-wedbush-pacgrow-healthcare-conference-301597404.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm Therapeutics participate in the 2022 Wedbush Pacgrow Healthcare Conference?

Karyopharm Therapeutics will participate in the conference on August 9, 2022, at 4:05 p.m. ET.

How can I access Karyopharm's fireside chat at the conference?

The fireside chat can be accessed via a live webcast on Karyopharm's website under the 'Events & Presentations' section.

How long will the webcast of Karyopharm's conference chat be available?

The webcast will be available for replay for 90 days following the event.

What is the focus of Karyopharm Therapeutics?

Karyopharm Therapeutics is focused on pioneering novel cancer therapies, particularly through its lead compound, XPOVIO.

What is Karyopharm's stock symbol?

Karyopharm Therapeutics' stock symbol is KPTI.